Compare STN & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STN | CYTK |
|---|---|---|
| Founded | 1954 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 10.4B |
| IPO Year | 2005 | 2004 |
| Metric | STN | CYTK |
|---|---|---|
| Price | $76.37 | $73.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 19 |
| Target Price | ★ $175.00 | $89.26 |
| AVG Volume (30 Days) | 320.6K | ★ 3.1M |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $11.06 | $7.37 |
| Revenue Next Year | $6.61 | $310.19 |
| P/E Ratio | $28.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $72.46 | $30.81 |
| 52 Week High | $114.52 | $80.20 |
| Indicator | STN | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 36.11 | 51.08 |
| Support Level | $72.46 | $73.00 |
| Resistance Level | $95.02 | $79.66 |
| Average True Range (ATR) | 3.16 | 2.57 |
| MACD | -0.10 | -0.53 |
| Stochastic Oscillator | 28.91 | 13.81 |
Stantec Inc is a sustainable engineering, architecture, and environmental consulting company. It offers services through the following business operating units; Environmental Services, Infrastructure, Water, Buildings, and Energy & Resources. Maximum revenue is derived from its Infrastructure business unit, which is engaged in evaluating, planning, and designing infrastructure solutions for transportation, community development, and urban spaces. The company's reportable segments are the United States, which derives maximum revenue, Canada, and Global. These segments provide consulting in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics services in the area of infrastructure and facilities.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.